| Name | Buformin hydrochloride |
| Description | Buformin hydrochloride (NSC-528218) is a potent AMPK activator,an oral antidiabetic drug of the biguanide class. Buformin delays the absorption of glucose from the gastrointestinal tract increases insulin sensitivity and glucose uptake into cells and inhibits synthesis of glucose by the liver. Biguanides may antagonize the action of glucagon, thus reducing fasting glucose levels. |
| In vitro | Buformin hydrochloride (0-10 mM; 5 days) inhibits SKBR3 and BT474 cells growth as a concentration-dependent manner, exhibits IC50 values of 246.7 μM and ?98.6 μM for erbB-2-overexpressing SKBR3 and BT474 cells, respectively[1].
Buformin hydrochloride (0-3 mM; 48 hours) increases the percentage of cells in G0/G1 phase and reduced the percentage of cells in S phase, especially in the SKBR3 cells[1].
Buformin hydrochloride (0-3 mM; 24 hours) suppresses RTK activation, including erbB-2 and IGF1R signaling downstream, and Akt activation/phosphorylation is inhibited in both SKBR3 and BT474 cells[1]. |
| In vivo | Buformin hydrochloride (oral administation; 7.6?mmol/kg of chow; 7 days) exhibits significantly reduced tumor volumes and weights, and?hinders mammary morphogenesis and proliferation in MMTV-erbB-2 transgenic mice[1]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (10.33 mM), Sonication is recommended.
DMSO : 60 mg/mL (309.79 mM), Sonication is recommended.
|
| Keywords | Type II diabete | SKBR3 | Inhibitor | inhibit | cervical cancer | Buformin hydrochloride | Buformin | BT474 | breast cancer | biguanide analog | antidiabetic | AMPK | AMP-activated protein kinase | agent | 1-Butylbiguanide |
| Inhibitors Related | Magnesium acetate tetrahydrate | Chromium(III) acetate | Metformin | Methyl cinnamate | Metformin hydrochloride | D-Arabinopyranose | Tranexamic acid | (E/Z)-10-Hydroxy-2-decenoic acid | Chitosan oligosaccharide | Isovaleric acid | Danthron | D-Arabinose |
| Related Compound Libraries | PI3K-AKT-mTOR Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Drug Repurposing Compound Library | Neuroprotective Compound Library | FDA-Approved Kinase Inhibitor Library | Anti-Cancer Approved Drug Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
United States
